University of Pennsylvania
-
Gilead’s Kite Unit Strikes Another Cell Therapy Deal to Pursue Next-Gen CAR T
Kite, the cell therapy unit of Gilead Sciences, is adding more tools to its cell therapy toolbox with the acquisition of Tmunity Therapeutics. It’s the company’s second cell therapy deal this month, following a partnership announced with clinical-stage Arcellx.
-
Penn spinout Capstan aims for next cell therapy frontier: in vivo cell engineering
Capstan Therapeutics, a University of Pennsylvania spinout, is now out of stealth with technology that could enable new medicines that work by engineering cells inside of a patient. Penn biotech pioneers Carl June and Drew Weissman are among the scientific co-founders of this startup, which aims to develop therapies for fibrosis, cancer, inflammation, and genetic diseases.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Genetic meds pioneer James Wilson has a new startup, this time in gene editing
Biotech startup iECURE is based on work from the University of Pennsylvania scientist, who has been researching ways to use in vivo gene editing as a way to “knock in” healthy versions of a gene to treat rare liver diseases. The company, which will develop therapeutic candidates from Penn, has raised $50 million in Series A financing.
-
MedCity Spotlight Video: How Penn is combating Covid-19
As part of MedCity’s 2021 INVEST conference, Cesar de la Fuente, presidential assistant professor at the University of Pennsylvania, explains the value of the rapid low-cost diagnostic test he has developed to detect SARS-CoV-2 and how the platform technology can be deployed to detect other diseases cost-effectively.
-
Policy makers should ‘set their sights higher’ on U.S. drug pricing regulations, researchers say
A review published in JAMA found that bills introduced into the House and Senate don’t go nearly as far as existing drug pricing regulations other countries. The researchers listed eight key lessons from six nations.
-
Artificial Intelligence, Diagnostics
UPenn, Intel partner to use federated learning AI for early brain tumor detection
The project will bring in 29 institutions from North America, Europe and India and will use privacy-preserved data to train AI models. Federated learning has been described as being born at the intersection of AI, blockchain, edge computing and the Internet of Things.
-
Data show early signs of efficacy for CRISPR-edited cell therapy in cancers
A team at UPenn led by CAR-T pioneer Carl June used CRISPR/Cas9 to engineer T cells for treating multiple myeloma and sarcoma. Data on three patients were published in Science. All the patients’ cancers ultimately progressed, though none had cytokine release syndrome.
-
UPenn study of CRISPR/Cas9 cell therapy in cancers doses first patients
NPR reported that the two patients, one with multiple myeloma and one with sarcoma, had received the gene-edited cell therapy as part of a Phase I trial.
-
Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies
The latest fund raise brings the total funding the company has received since May to $88 million, which it will use to develop CAAR-T therapies, similar to CAR-Ts used in cancers.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Cabaletta raises $38M to develop CAR-T-like cell therapies for autoimmune diseases
The company plans to file an IND in the second half of 2019. The company CEO says the “CAAR-T” therapies may avoid some of the potentially fatal toxicity risks of CAR-Ts for blood cancers.
-
Recently published CAR-T mishap could pose challenges for Novartis, Gilead and others
A manufacturing error during a clinical trial of Kymriah, now marketed by Novartis, is less likely today, but could be an issue as CAR-Ts move into earlier therapy lines.
-
New wellness study shows just how sticky wearables can be, even among seniors
The interest in improving the sustained use of wearables goes beyond employer programs, according to the Annals of Internal Medicine study. It also applies to data collection for precision medicine initiatives to better target interventions.